Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -215.26% is in line with its 5-year average of -200.78%, around the middle of its 5-year range (-293.78%–-105.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.54% below its 12-month average of -205.91%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -215.26%.
RETURN ON EQUITY (ROE)
-215.26%
RETURN ON EQUITY (ROE) AVG TTM
-205.91%
RETURN ON EQUITY (ROE) AVG 3Y
-205.91%
RETURN ON EQUITY (ROE) AVG 5Y
-200.78%
RETURN ON EQUITY (ROE) AVG 10Y
-172.61%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.54%
CURRENT VS 3Y AVG
-4.54%
CURRENT VS 5Y AVG
-7.21%
CURRENT VS 10Y AVG
-24.71%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.92%
median of 594 covered companies
CURRENT VS SECTOR MEDIAN
-439.15%
vs the sector median at left
Coherus Oncology, Inc.
Market Cap
$164.54M
Return on Equity (ROE)
-215.26%
TTM Avg
-205.91%
3Y Avg
-205.91%
5Y Avg
-200.78%
Market Cap
$163.12M
Return on Equity (ROE)
-60.19%
TTM Avg
-68.34%
3Y Avg
-61.91%
5Y Avg
-47.91%
Market Cap
$167.32M
Return on Equity (ROE)
3.51%
TTM Avg
-6.60%
3Y Avg
-9.04%
5Y Avg
-6.71%
Market Cap
$169.21M
Return on Equity (ROE)
-31.32%
TTM Avg
4.38%
3Y Avg
4.09%
5Y Avg
11.26%
Market Cap
$157.30M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$172.45M
Return on Equity (ROE)
-56.61%
TTM Avg
-75.88%
3Y Avg
-88.15%
5Y Avg
-30.55%
Market Cap
$157.44M
Return on Equity (ROE)
N/A
TTM Avg
101.44%
3Y Avg
117.16%
5Y Avg
-25.56%
Market Cap
$172.78M
Return on Equity (ROE)
-47.36%
TTM Avg
-30.00%
3Y Avg
-33.39%
5Y Avg
-32.72%
Market Cap
$155.86M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | $164.54M | -215.26% | -205.91% | -205.91% | -200.78% |
| PepGen Inc. (PEPG)vs › | $163.12M | -60.19% | -68.34% | -61.91% | -47.91% |
| OptimizeRx Corp. (OPRX)vs › | $167.32M | 3.51% | -6.60% | -9.04% | -6.71% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | -31.32% | 4.38% | 4.09% | 11.26% |
| Inogen, Inc. (INGN)vs › | $157.30M | -14.07% | -16.23% | -27.66% | -19.01% |
| MediWound Ltd. (MDWD)vs › | $172.45M | -56.61% | -75.88% | -88.15% | -30.55% |
| Minerva Neurosciences, Inc. (NERV)vs › | $157.44M | N/A | 101.44% | 117.16% | -25.56% |
| Nkarta, Inc. (NKTX)vs › | $172.78M | -47.36% | -30.00% | -33.39% | -32.72% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | 13.51% | 15.58% | 15.05% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | -59.40% | -255.06% | -160.44% | -112.56% |
ROE
-215.3%
ROA
-68.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -215.26% |
| 2026-03-31 | -192.90% |
| 2025-12-31 | -279.10% |
| 2025-09-30 | -209.30% |
| 2025-06-30 | -132.98% |
| 2021-12-31 | -293.78% |
| 2021-09-30 | -177.17% |
| 2021-06-30 | -105.75% |
| 2021-03-31 | -59.74% |
| 2020-12-31 | 47.07% |
| 2020-09-30 | 63.26% |
| 2020-06-30 | 84.77% |
| 2020-03-31 | 92.46% |
| 2019-12-31 | 85.38% |
| 2019-09-30 | -21.40% |
| 2018-06-30 | -310.25% |
| 2017-12-31 | -779.99% |
| 2017-09-30 | -471.61% |
| 2017-06-30 | -379.89% |
| 2017-03-31 | -174.90% |
| 2016-12-31 | -657.94% |
| 2016-09-30 | -315.79% |
| 2015-09-30 | -499.51% |
| 2015-06-30 | -141.69% |
| 2015-03-31 | -269.16% |
| 2014-12-31 | -130.52% |
| 2014-09-30 | -777.69% |
| 2014-06-30 | -586.77% |
